Ginkgo Bioworks Stock
Custom Microbes Design
Sign up today and learn more about Ginkgo Bioworks Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Ginkgo Bioworks Stock
Ginkgo Bioworks is a biotech company that designs custom microbes. The company creates custom microbes for three main areas: cultured ingredients, strain improvement, and enzymes. For cultured ingredients, Ginkgo Bioworks creates engineered yeasts to produce ingredients via fermentation for perfumes, foods, cosmetics, etc. For strain improvement, Ginkgo Bioworks engineers in-use organisms to improve efficiency and sustainability. For enzymes, Ginkgo Bioworks aims to discover "better" enzymes for various applications, such as cheesemaking and pharmaceuticals.
Ginkgo Bioworks' platform consists of its Foundries and Codebase. Foundries are Ginkgo Bioworks way to automate organism design and Codebase is Ginkgo Bioworks' library of cell, enzyme and genetic programs that help jumpstart new programs and discoveries.
Ginkgo Bioworks was founded in 2009. The company is based in Boston, Massachusetts.
Investors
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Senator Investment Group
Relativity Space, Commonwealth Fusion, Ginkgo Bioworks, Animoca Brands
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Apeel Sciences, Adaptive Biotechnologies, Arctic Wolf, Talkdesk, Druva, Color, Clip, Iterable
General Atlantic
AppDynamics, Toutiao, Chime, Wish, Avant, Articulate, Bolt Financial, Automation Anywhere, Coalition, Blend
Cascade Investment
Convoy, Delos, Schrodinger, OANDA Corporation, Ginkgo Bioworks
Funding History
July 2015 | $20K |
---|---|
June 2016 | $37K |
October 2017 | $109K |
September 2019 | $232K |
Management
Chief Executive Officer
Jason Kelly
Co-Founder
Barry Canton
Co-Founder
Austin Che
Co-Founder
Tom Knight
Co-Founder
Reshma Shetty
Press
endpts - Sep, 10 2020
Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibodyTechCrunch - Aug, 26 2020
Synthetic biology startups are giving investors an appetitefinsmes - May, 28 2020
Ginkgo Receives $70M InvestmentWall Streets Journal - Apr, 30 2020
Ginkgo Bioworks Redirects Its Biotech Platform to CoronavirusPR Newswire - Apr, 15 2020
Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response